common.study.topics.clinical

Testing Experimental Medication in Healthy Subjects

common.study.values.description

A Study on the Impact of Rabeprazole-induced Elevated Stomach pH on APO-Dabigatran Exposure in Healthy Volunteers

Open-label, crossover study recruiting 46 healthy male volunteers comparing the absorption of APO-dabigatran 150 mg per oral (PO) in the absence or presence of a proton pump inhibitor. Participants will serve as their own control when comparing dabigatran exposure in the absence or presence of the proton pump inhibitor, Rabeprazole 20 mg.

common.study.values.location

participant.ui.study.affiliations-map.online-study.header-virtual

participant.ui.study.affiliations-map.online-study.text

participant.ui.study.affiliations-map.legend.locations participant.ui.study.affiliations-map.legend.selected

common.study.values.methods

Pharmaceutical medication involved common.study.methods.has-drugs-yes
Patients and healthy individuals accepted common.study.methods.is-healthy-no

Drug - RABEprazole 20 Mg Oral Delayed Release Tablet

Absorption of APO-Dabigatran measured with and without influence of rabeprazole

Drug - APO-Dabigatran 150mg

Absorption of APO-Dabigatran post single dose

participant.views.study.view.additional

participant.views.study.view.scientific-title

Impact of Rabeprazole-induced Elevated Gastric pH on APO-Dabigatran Exposure in Healthy Volunteers

common.study.values.clinical-trial-id

NCT04157881

participant.views.study.view.id

aQW4Yd